Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease.
about
The promise of neuroprotective agents in Parkinson's diseaseBrain region specific mitophagy capacity could contribute to selective neuronal vulnerability in Parkinson's diseaseThe role of oxidative stress in Parkinson's diseaseOxidative stress-induced signaling pathways implicated in the pathogenesis of Parkinson's diseaseDegeneration of Dopaminergic Neurons Due to Metabolic Alterations and Parkinson's DiseaseRelevance of the glutathione system in temporal lobe epilepsy: evidence in human and experimental modelsMechanisms of altered redox regulation in neurodegenerative diseases--focus on S--glutathionylationThe role of free radicals in the aging brain and Parkinson's Disease: convergence and parallelismParkinson's disease as a result of agingGlutathione depletion and overproduction both initiate degeneration of nigral dopaminergic neuronsOxidative inactivation of mitochondrial aconitase results in iron and H2O2-mediated neurotoxicity in rat primary mesencephalic cultures.Selective neuronal vulnerability to oxidative stress in the brain.Apoptosis modulators in the therapy of neurodegenerative diseases.Astrocytes and therapeutics for Parkinson's disease.Does neuronal loss in Parkinson's disease involve programmed cell death?Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways.4-Hydroxynonenal, a product of oxidative stress, leads to an antioxidant response in optic nerve head astrocytes.A Cystine-Rich Whey Supplement (Immunocal(®)) Delays Disease Onset and Prevents Spinal Cord Glutathione Depletion in the hSOD1(G93A) Mouse Model of Amyotrophic Lateral SclerosisMitochondria: redox metabolism and dysfunction.X-ray absorption spectroscopy at the sulfur K-edge: a new tool to investigate the biochemical mechanisms of neurodegeneration.Recent advances in the treatment of neurodegenerative diseases based on GSH delivery systems.Drug bioactivation, covalent binding to target proteins and toxicity relevance.Neuroprotective effect of nerolidol against neuroinflammation and oxidative stress induced by rotenone.A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease.Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?Oxidative and nitrative protein modifications in Parkinson's diseaseUse of proteomics for the identification of novel drug targets in brain diseases.Redox imbalance in Parkinson's disease.Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic interventionGlutathione deficiency in Gclm null mice results in complex I inhibition and dopamine depletion following paraquat administrationA FRET-based method to study protein thiol oxidation in histological preparationsGlutathione metabolism and Parkinson's disease.Glutathione depletion in immortalized midbrain-derived dopaminergic neurons results in increases in the labile iron pool: implications for Parkinson's disease.Targeting the progression of Parkinson's disease.Glutathione dysregulation and the etiology and progression of human diseases.Resveratrol protects DAergic PC12 cells from high glucose-induced oxidative stress and apoptosis: effect on p53 and GRP75 localization.Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease.The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease: A Mini Review.Relationships between Stress Granules, Oxidative Stress, and Neurodegenerative Diseases.
P2860
Q21129436-B7D4D4BD-C363-4B6F-93A2-E747AD1C7091Q21245635-B54C510D-BD4B-4747-848B-58980E57272DQ24307946-6983745C-C5CA-4A93-88B8-8092643A7054Q24337079-ACA375BC-AD5B-47A6-BE29-CA27DEC77CBBQ26750370-461242E0-7F0E-4EB2-BEA0-FA3028FD0F61Q26830615-ABA4102D-DA35-4AD9-BAF0-C71094D10B7BQ26830954-B5CADFF4-81FD-42A8-9206-9E5BB369836AQ26852148-A6B1A5D0-7BC2-4E94-BD80-ACDEFC913CBCQ28084395-D92060FF-8975-4D88-9DEC-470507CF6AE0Q30498761-86B580DB-604A-4137-A60C-AD69B4331FD6Q33504558-E079E2EA-DC2D-4C40-8185-5D4C2DDDF92CQ33868370-FC40CB0A-4A9A-495A-A46B-43912E65224DQ34074800-AD434315-1DE8-4748-81E6-7CCB4FD5C4DEQ34168266-60910E2E-AF55-427D-B6EC-875A3D08B7C3Q34312949-56131B09-E764-4EAE-A2B4-1BAB70E34142Q35696249-9FFFCBD9-A845-4F43-9DD9-2EF0F51B0E87Q35698825-47424843-5F4F-46BE-897A-E78C844C2754Q35897919-704E4707-E4F7-40BF-A2A7-66A574C195A4Q35944831-26DF8776-1280-4A48-B736-F822CBAFA644Q36015551-A6EAAB7A-3A25-424C-9854-6AACC3C94927Q36023685-722765E9-FFAC-4FF0-81A4-B3BA4467C428Q36061821-AA6CB2E3-CD6C-47FF-9694-A17A466CB0C8Q36109494-13A47CCD-8A04-41FF-B3DE-894F4A8B101DQ36172557-084686FA-3986-4D9F-BA5F-C78A94D4FFA9Q36272936-F31CA375-DF0D-4CFE-B2A2-EE32886D9711Q36499640-F98EBEC1-DC04-4A1D-887C-BD0324BC83CEQ36710261-9FC4D138-425F-40CA-BE29-C17B6B8506C7Q36785927-32731FF0-3BC8-46A0-B1EA-66B6EC06604CQ36899782-750F200D-587C-4607-B2E0-8905A3B928C7Q36919403-DF2F7C17-6D8B-4942-B667-6DD44D7551B4Q37000031-E97E5AAA-9ECC-4C5A-AECB-029794A9EBD3Q37021476-E3E1FA5D-B21A-496F-9453-16421D91D9A8Q37078480-E4B92A66-FEC2-4A9C-B2AC-C0A76B772652Q37178356-20C663D8-186B-40C5-9A1B-C195FF50EFB6Q37299619-071A44AF-17B1-46EB-9275-DCA44DFD3EA2Q37372896-E33666AC-FFF1-40F5-96E5-1D5B103591C5Q37470082-D5666708-F56E-4B2F-9D1F-A76A18D996CDQ37539279-F0726929-73C5-4048-BBD1-57A3182B3CDFQ37575502-150A149A-8612-427D-BB76-3FEDC3DBE0D0Q37618198-93C86EC6-8096-4A5A-9D32-A8636ABB75B3
P2860
Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Alterations in the distributio ...... nigra in Parkinson's disease.
@en
type
label
Alterations in the distributio ...... nigra in Parkinson's disease.
@en
prefLabel
Alterations in the distributio ...... nigra in Parkinson's disease.
@en
P50
P356
P1476
Alterations in the distributio ...... nigra in Parkinson's disease.
@en
P2888
P304
P356
10.1007/BF01291884
P4011
86883201906a3544a103dbfa4228ba6e01b903f7
P577
1997-01-01T00:00:00Z